Global Opioids Drug Market Forecast 2019-2027

LONDON, Dec. 4, 2018 /PRNewswire/ -- KEY FINDINGSThe global opioids drugs market is anticipated to grow at a CAGR of 2.52% between 2019 and 2027. Opioids are narcotic drugs and mostly directed for pain management. Increasing case of road accidents & surgical procedures are the main drivers that are propagating the global market growth for opioids drugs.Download the full report: https://www.reportbuyer.com/product/5637933 MARKET INSIGHTSThe opioid drugs are commonly used for alleviating the post-operative pains caused by surgical procedures.Opioid drugs are approved by FDA in the United States with ADF labeling and are currently marketed in North America.The market is segmented by products and applications, out of which, the former's oxycodone sub-segment is estimated to hold the highest market share in 2018.Growing demand for palliative care that aims to improve the quality of life for the patient suffering from terminal illness by implementing the use of opioid drugs is further driving the said market's growth.The growing opioid addiction crisis is leading to submission of lawsuits against pharmaceuticals companies who are manufacturing the opioid drugs.REGIONAL INSIGHTSThe global market for opioid drugs is geographically segmented into four regions, namely, North America, Asia-Pacific, Europe and countries from the Rest of the World.The North American economy holds the largest share for the market by revenue in the forecast years.The recurrently increasing geriatric population who are prone to irreversible and incurable disorders and chronic diseases are further enhancing the demand for pain management treatments in the market. Investments from local, regional players in the development of abuse-deterrent morphine drug are attributing for a high growth rate of morphine drug in the region.COMPETITIVE INSIGHTSAcura Pharmaceuticals, Inc., Allergan PLC, BioDelivery Sciences International, Inc., Cipher Pharmaceuticals, Inc., Collegium Pharmaceutical, Inc., Daiichi Sankyo, Inc., Egalet Corp., Hikma Pharmaceuticals PLC, Indivior, Inc., Insys Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Johnson & Johnson, Lannett Co. Inc., Lupin Ltd., Mylan NV, Pfizer, Inc., Purdue Pharma LP, Sanofi-Aventis S.A., Sun Pharmaceutical Industries Limited (Sun Pharma) and Teva Pharmaceutical Industries Ltd. are some of the key market players who are dominating the global opioids market.Companies mentioned1. ACURA PHARMACEUTICALS, INC.2. ALLERGAN PLC3. BIODELIVERY SCIENCES INTERNATIONAL, INC.4. CIPHER PHARMACEUTICALS INC.5. COLLEGIUM PHARMACEUTICAL, INC.6. DAIICHI SANKYO, INC.7. EGALET CORP.8. HIKMA PHARMACEUTICALS PLC9. INDIVIOR INC.10. INSYS THERAPEUTICS, INC.11. JANSSEN PHARMACEUTICALS, INC.12. JOHNSON & JOHNSON13. LANNETT CO. INC.14. LUPIN LTD.15. MYLAN NV16. PFIZER INC.17. PURDUE PHARMA LP18. SANOFI-AVENTIS S.A.19. SUN PHARMACEUTICAL INDUSTRIES LIMITED (SUN PHARMA)20. TEVA PHARMACEUTICAL INDUSTRIES LTD.Download the full report: https://www.reportbuyer.com/product/5637933 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +1 (718) 213 4904 Website: www.reportbuyer.com

View original content:http://www.prnewswire.com/news-releases/global-opioids-drug-market-forecast-2019-2027-300759945.html

SOURCE ReportBuyer

Latest Press Release on Drug News

UT Health San Antonio to lead $11 million, NIH-funded study of a first-ever oral chlamydia vaccine

The University of Texas Health Science Center at San Antonio (UT Health San Antonio) will direct a team of researchers to investigate a novel oral vaccine for chlamydia, the most rep...

GIBF invests $10 Million in Nectin Therapeutics to Advance Novel Pipeline of First-in-Class Immunotherapies and Antibody Drug Conjugates

Proceeds from financing to support ongoing clinical development of lead program targeting PVR as well as IND-enabling activities for multiple ADC candidates TEL AVIV, Israel , ...

Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons

A real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID) examined three consecutive U.S. flu seasons in the United States . The study suggests th...

Foresee Pharmaceuticals Announces First Subject Dosed in its First-in-Human Clinical Trial of FP-020

TAIPEI , April 30, 2024 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced that the first subject has been dosed in its Phase 1 clinical trial of FP...

PANTHERx® Rare Partnering with X4 Pharmaceuticals Inc. for the Distribution of XOLREMDI™ (mavorixafor), the First FDA-Approved Therapy Indicated for Use in Patients with WHIM Syndrome

PITTSBURGH , April 29, 2024 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, today announced it was selec...